DAX20.986 +0,4%ESt505.164 +0,3%Top 10 Crypto17,08 +3,1%Dow43.488 +0,8%Nas19.630 +1,5%Bitcoin103.769 +5,2%Euro1,0392 +1,2%Öl80,00 -0,9%Gold2.706 +0,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 Tesla A1CX3T ByteDance BYT111 Commerzbank CBK100 Bayer BAY001 Deutsche Bank 514000 Siemens Energy ENER6Y Trump Media Technology A3CYXD Novo Nordisk A3EU6F MicroStrategy 722713 BASF BASF11 Allianz 840400 Mercedes-Benz Group (ex Daimler) 710000 Amazon 906866
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Trumps Amtsantritt im Fokus: DAX erstmals über 21.000-Marke -- Neuer Bitcoin-Rekord -- LANXESS: Starke Zahlen -- Commerzbank vor Jobabbau -- Rheinmetall, Delivery Hero, Siemens Energy im Fokus
Top News
BÖRSE AKTUELL: DAX erstmals über 21.000-Punkte-Marke - Neuer Rekord vor Trumps Amtseinführung BÖRSE AKTUELL: DAX erstmals über 21.000-Punkte-Marke - Neuer Rekord vor Trumps Amtseinführung
TikTok nach vorübergehendem Blackout schon wieder online - Trump will Joint Venture TikTok nach vorübergehendem Blackout schon wieder online - Trump will Joint Venture
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Halozyme Therapeutics Aktie

NeuKaufenVerkaufen
53,04 EUR -0,76 EUR -1,41 %
FSE
54,79 USD -0,55 USD -0,99 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.6,76 Mrd. EUR

KGV17,61Div. Rendite0,00%

WKNA0DLHS

ISINUS40637H1095

SymbolHALO

Halozyme Therapeutics Aktien News

DatumMeistgelesen
PR NewswireHalozyme to Present at Upcoming Investor Conferences
PR NewswireHalozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain
PR NewswireHALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS
PR NewswireHalozyme To Report Second Quarter 2023 Financial and Operating Results
PR NewswirePositive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
PR NewswirePositive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis
PR NewswireHalozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use in Generalized Myasthenia Gravis
PR NewswireCanadian Investment Regulatory Organization Trading Halt - HALO
PR NewswireCanadian Investment Regulatory Organization Trading Halt - HALO
PR NewswireHalozyme to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
PR NewswireHALOZYME REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATING RESULTS
PR NewswireHalozyme to Present at Upcoming Investor Conferences
PR NewswireHalozyme To Report First Quarter 2023 Financial and Operating Results
PR NewswireHALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE
PR NewswireHALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESULTS
PR NewswireHalozyme to Report Fourth Quarter and Full Year 2022 Financial and Operating Results
PR NewswireHalozyme Appoints Barbara Duncan to its Board of Directors
PR NewswireHALOZYME THERAPEUTICS, INC. ANNOUNCES REDEMPTION OF 1.25% CONVERTIBLE SENIOR NOTES DUE 2024
PR NewswireHalozyme Provides 2023 Financial Guidance and Outlook
PR NewswireHalozyme to Present at the 41st Annual J.P. Morgan Healthcare Conference
PR NewswireHalo Collective Reports Highest Selling Quarter for Budega Retail Locations and Plans to Continue Expansion
PR NewswireHalo Collective Reports Third Quarter 2022 Financial Results
PR NewswireHalo Collective Enters into Convertible Promissory Note for Aggregate Principal Amount of Up To C$5 Million
PR NewswireHalozyme to Participate in Upcoming Investor Conferences
PR NewswireHALOZYME REPORTS THIRD QUARTER 2022 FINANCIAL AND OPERATING RESULTS
PR NewswireHalozyme to Report Third Quarter 2022 Financial and Operating Results
PR NewswireHalo Announces Update to Proposed Share Consolidation
PR NewswireHalo Collective Completes Acquisition of Premium Indoor Grow and Distribution Hub in Portland, Oregon
PR NewswireHalo Collective and Alpha Blue Ocean Agree to Early Termination of Loan and Convertible Debentures Agreements
PR NewswireHalozyme to Participate in the 2022 Wells Fargo Healthcare Conference
PR Newswire/R E P E A T -- Halo Collective Appoints Katie Field as Chairman of the Board/
PR NewswireHalo Collective Appoints Katie Field as Chairman of the Board
PR NewswireHalo Collective Receives All Regulatory Approvals for its Third Budega™ Dispensary in Hollywood, Halo's first Superstore
PR NewswireHALOZYME REPORTS SECOND QUARTER 2022 FINANCIAL AND OPERATING RESULTS
PR NewswireHalo Collective Congrats Akanda Corp. on Cansativa Supply Agreement for Europe
PR NewswirePositive Results Announced from Phase III IMscin001 Study Evaluating Subcutaneous Formulation of Tecentriq® with ENHANZE® in Advanced Non-Small Cell Lung Cancer
PR NewswireHalozyme to Report Second Quarter 2022 Financial and Operating Results
PR NewswireHalo Collective Promotes Katharyn Field to Chief Executive Officer
PR NewswireHalo Collective Promotes Katharyn Field to Chief Executive Officer
PR NewswireConcerned Shareholders of Akanda Corp. Replace a Majority of Akanda's Board of Directors
Wer­bung

Halozyme Therapeutics News

Halozyme Therapeutics News: auf dieser Seite finden Sie alle Halozyme Therapeutics News und Nachrichten zur Halozyme Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Halozyme Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Halozyme Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.